Fig. 2

Increased frequency and activity of CD8⁺ T cells in responders to anti-PD1 treatment. B16F10-Luc tumor-bearing mice were treated with 100 μg of anti-PD1 (black filled inverted triangle) on day 10, day 14, and day 18. Tumors were obtained 15 d after initiating the anti-PD1 treatment. a Average (left) and individual (right) tumor volume following anti-PD1 treatment in B16F10-Luc tumor-bearing mice (non-responders, n = 8; responders, n = 6). b Response assessed by % of tumor growth between d 18 and d 25 post-tumor inoculation. (non-responders, n = 8; responders, n = 6). c Tumor weight after anti-PD1 treatment. (non-responders, n = 8; responders, n = 6). d Frequency of cytotoxic CD8⁺ T cells (gated on the CD45⁺ CD3⁺ CD8⁺ population) (n = 6/group). e Population percentages of Granzyme B⁺ and IFNγ⁺ in tumor-infiltrating CD8⁺ T cells as determined by flow cytometry (n = 6/group). f Relative mRNA expression of Cxcl9 and Cxcl10 in tumors of non-responders and responders (n = 6/group). Data are presented as mean ± SEM. Statistical significance was determined using a two-tailed Student’s t-test. Data shown are representative of three independent experiments performed. *p < 0.05; **p < 0.01; ****p < 0.0001